Xilio Therapeutics welcomes Christina Rossi to its Board of Directors

– USA, MA –  Xilio Therapeutics, a biotechnology company developing, tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Christina Rossi to its board of directors.

“I am very pleased to welcome Christy to our board of directors during this exciting phase of growth for our company,” said Board chairman, Dan Lynch. “Christy is a leader with a proven track record of shaping corporate strategy and leading companies through various stages of development. As we head toward plans to initiate clinical development of our lead candidates, her unique and forward-looking perspective compliments those of the current board members and will provide important insights to Xilio as we plan for the future.”

About Christina Rossi

Ms. Rossi joins the Xilio board of directors with 20 years of experience in the pharmaceutical and biotechnology industries. She is currently the chief commercial officer of Blueprint Medicines and played a critical role in the U.S. launches of AYVAKIT and GAVRETO in certain genomically defined cancers. Before joining Blueprint Medicines, she served in various roles at Sanofi Genzyme, leading the launches of several new multiple sclerosis therapies, and optimized operations to expand patient access. Ms. Rossi’s positions at Sanofi Genzyme included serving as the MS business unit head of North America; vice president, MS sales; and vice president, MS patient, and provider services.

Before joining Sanofi Genzyme, Ms. Rossi held various roles at Biogen, Inc, leading brands and a biosimilar-focused venture. Ms. Rossi also consulted within the healthcare practice of Boston Consulting Group.

Ms. Rossi holds a Bachelor of Science in biology from Duke University and a Master of Business Administration from Harvard Business School.

About Xilio Therapeutics

Xilio Therapeutics is a privately-held biotechnology company that uses its proprietary technology to engineer potent cancer immunotherapies that have the potential to unleash the power of the immune system selectively at the site of the tumor. Xilio has designed its investigational therapies to maximize efficacy and overcome the significant toxicities associated with certain clinically validated immuno-oncology therapies, positioning them as potential treatments for a significant number of patients. The company’s proprietary pipeline includes XTX202, a tumor-selective modified form of IL-2, and XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, as well as tumor-selective IL-12 and IL-15 research programs. Xilio was founded in 2016 and is headquartered in Waltham, Mass.

For more information: https://www.xiliotx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.